Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma
| dc.contributor.author | Arman Karakaya, Yeliz | |
| dc.contributor.author | Gokoz Dogu, Gamze | |
| dc.contributor.author | Baser Oncel, Sevin | |
| dc.contributor.author | Gormez, Aysegul | |
| dc.contributor.author | Bir, Ferda | |
| dc.date.accessioned | 2022-03-15T10:29:56Z | |
| dc.date.available | 2022-03-15T10:29:56Z | |
| dc.date.issued | 2021 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of platinum-based chemotherapy in non–small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between platinum-based chemotherapy. Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors from 81 patients. Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors (p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p =0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with squamous cell carcinoma (p = 0.037). Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies. | en_US |
| dc.identifier.citation | Karakaya, Y. A., Dogu, G. G., Oncel, S. B., Gormez, A., & Bir, F. (2021). Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research, | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/55636 | |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Annals of Medical Research | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma | en_US |
| dc.type | Article | en_US |
